Global Nosocomial Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431735
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Abbott
  • Belimed
  • BioMérieux
  • Cepheid
  • Johnson & Johnson
  • Merck & Co
  • MORE
Nosocomial Infection Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017-2025, the global nosocomial infection treatment market was valued at US$ 29,993.2 Mn in 2017, and is expected to reach US$ 45,932.5 Mn by 2025, expanding at a CAGR of 2.5% from 2017 to 2025.

Market Insights

Nosocomial infection, also known as hospital acquired or associated infection (HAI) is defined as an infection developed in patients during the hospital stay that was earlier not present or incubated during admission in the hospital. Nosocomial infection is majorly caused by bacteria, virus, or fungal pathogen and is becoming the leading cause of morbidity and mortality globally, causing enormous economic burden. The nosocomial infection treatment market is anticipated to grow throughout the forecast period. Major factors contributing to the growth of the HAI market is rising prevalence of the nosocomial infection, increasing government initiatives and rising public awareness related to the quality hygiene in hospitals, rising geriatric population immuno-compromised patient, advances in air handling units and other cleaning technologies. Multi-drug resistance is observed in patients mainly due to excessive use of antibiotic which is one of the causes of rising prevalence of nosocomial infection. The regulatory authorities have created set of guidelines for hospitals and clinics and instructed them to abide by these guidelines for prevention of nosocomial infection and adopt best health practices along with a devised strategy to control infections.

The global nosocomial infection treatment market are segmented by infection type as pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA, others. Pneumonia, urinary tract infection (UTI), surgical site infection (SSI) and MRSA are the major types of hospital acquired infections that find the highest prevalence.

Nosocomial infection treatment market is segmented on the basis of treatment type as antibacterial, antifungal, antiviral treatment and others. Antibacterial treatment accounted for the largest market share in 2015. As of the current market scenario, North America is the largest regional market for nosocomial infection treatment, followed by Europe and Asia Pacific. North America dominates the global nosocomial infection treatment market attributed to rise in prevalence of nosocomial infections, mounting cases of multi-drug resistant microbial infections and rising demand for advanced therapeutics. Asia Pacific is anticipated to be the fastest growing market during the forecast period. The key factors responsible for its significant growth are emerging economies with developing healthcare market due to pouring investments in healthcare infrastructure by public and private sector, increase in prevalence of nosocomial infection, and high health awareness coupled with growing disposable income.

Market Competition Assessment

Key players in the nosocomial infection treatment market are Abbott Vascular Inc., Bayer, Becton, Dickinson and Company, Belimed, BioMerieux, Cantel, Cepheid, Getinge Group, Kimberly-Clark Corp., Merck & Co, Nordion, Pfizer, Roche, Sakura Seiki, BioMérieux, Steris, Johnson & Johnson, Sterigenics International, Inc., Halyard Health, Inc., Advanced Sterilization Products, Matachana Group etc.

Key Market Movements:
  • Rise in prevalence of nosocomial infection due to an increase in patient pool of chronic diseases, growth in geriatric population which are more prone to infection
  • With increase in number of surgical procedures with medical advancement is potential risk for the patient due to infection caused by the surgical equipment’s or by healthcare workers; patient compromise with immunity are more vulnerable to infection
  • In emerging economies, the rise in number of hospital increases the chances of nosocomial infection thus leading to growth of hospital infection prevention and control market
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott
  • Belimed
  • BioMérieux
  • Cepheid
  • Johnson & Johnson
  • Merck & Co
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Nosocomial Infection Treatment Portraiture
2.2 Global Nosocomial Infection Treatment Share, by Infection Type, 2015 (US$ Mn)
2.3 Global Nosocomial Infection Treatment, by Treatment Type, 2015 (US$ Mn)
2.4 Global Nosocomial Infection Treatment, by Geography, 2015 (Value %)

Chapter 3 Global Nosocomial Infection Treatment Analysis
3.1 Global Nosocomial Infection Treatment Overview
3.2 Epidemiology of Nosocomial Infections
3.3 Guidelines for Nosocomial Infection Control
3.4 Market Dynamics
3.4.1 Market Drivers
3.4.2 Challenges
3.4.3 Opportunities
3.5 Attractive Investment Proposition, 2015
3.6 Market Positioning Analysis of Key Players: Nosocomial Infection Treatment Market, 2015

Chapter 4 Global Nosocomial Infection Treatment Analysis, by Infection Type, 2015 - 2025 (US$)
4.1 Introduction
4.2 Ventilator Associated Pneumonia
4.3 Urinary Tract Infection
4.4 Blood Stream Infection
4.5 Surgical Site Infection
4.6 Gastrointestinal Infection
4.7 MRSA
4.8 Others (ENT Infections, Skin Infection, and Bone Infection)

Chapter 5 Nosocomial Infection Treatment Analysis, by Treatment Type, 2015 - 2025 (US$)
5.1 Introduction
5.2 Antibacterial Treatment
5.3 Antiviral Treatment
5.4 Antifungal Treatment
5.5 Others

Chapter 6 Global Nosocomial Infection Treatment, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa

Chapter 7 CompanyProfiles

7.1 Abbott
7.2 Bayer
7.3 Becton, Dickinson and Company
7.4 Belimed
7.5 BioMerieux
7.6 Cantel
7.7 Cepheid
7.8 Getinge Group
7.9 Kimberly-Clark Corp.
7.10 Merck & Co
7.11 Nordion
7.12 Pfizer
7.13 Roche
7.14 Sakura Seiki
7.15 BioMérieux
7.16 Steris
7.17 Johnson & Johnson
7.18 Sterigenics International, Inc.
7.19 Halyard Health, Inc.
7.20 Advanced Sterilization Products
7.21 Matachana Group
7.22 Other Notable Players

List of Figures
Fig. 1 Global Nosocomial Infection Treatment: Research Methodology
Fig. 2 Global Nosocomial Infection Treatment Share, by Infection, 2015 (US$ Mn)
Fig. 3 Global Nosocomial Infection Treatment, by Application Type, 2015 (US$ Mn)
Fig. 4 Global Nosocomial Infection Treatment, by Geography, 2015 (Value %)
Fig. 5 Attractive Investment Proposition: Global Nosocomial Infection Treatment, by Geography
Fig. 6 Competitive Analysis: Key Players in Global Nosocomial Infection Treatment
Fig. 7 Global Ventilator Associated Pneumonia Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Urinary Tract Infection Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Blood Stream Infection Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Surgical Site Infection Market, 2015 - 2025 (US$ Mn)
Fig. 11 Global Gastrointestinal Infection Market, 2015 - 2025 (US$ Mn)
Fig. 12 Global MRSA Market, 2015 - 2025 (US$ Mn)
Fig. 13 Global Others (ENT Infections, Skin Infection, and Bone Infection) Market, 2015 - 2025 (US$ Mn)
Fig. 14 Global Antibacterial Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 15 Global Antiviral Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 16 Global Antifungal Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 17 Global Other Treatment Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Nosocomial Infection Treatment, By Infection Type 2015 - 2025 (US$ Mn)
Table 2 Nosocomial Infection Treatment, by Treatment Type, 2015 - 2025 (US$ Mn)
Table 3 Global Nosocomial Infection Treatment, by Geography, 2015 - 2025 (US$ Mn)
Table 4 North America Nosocomial Infection Treatment, by Country, 2015 - 2025 (US$ Mn)
Table 5 Europe Nosocomial Infection Treatment, by Country, 2015 - 2025 (US$ Mn)
Table 6 Asia-Pacific Nosocomial Infection Treatment, by Country, 2015 - 2025 (US$ Mn)
Table 7 Latin America Nosocomial Infection Treatment, by Country, 2015 - 2025 (US$ Mn)
Table 8 Middle East and Africa Nosocomial Infection Treatment, by Country, 2015 - 2025 (US$ Mn)
Table 9 Abbott, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 10 Bayer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 11 Becton, Dickenson and Company: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 12 Belimed: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
Table 13 BioMerieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 14 Cantel: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 15 Cepheid: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 16 Gettinge Group: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 17 Kimberly- Clark Corp.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 18 U Merck & Co: Company Snapshot (Business Description; Financial PFIG. 1 Global Nosocomial Infection Treatment: Research Methodology
Fig. 2 Global Nosocomial Infection Treatment Share, by Infection, 2015 (US$ Mn)
Fig. 3 Global Nosocomial Infection Treatment, by Application Type, 2015 (US$ Mn)
Fig. 4 Global Nosocomial Infection Treatment, by Geography, 2015 (Value %)
Fig. 5 Attractive Investment Proposition: Global Nosocomial Infection Treatment, by Geography
Fig. 6 Competitive Analysis: Key Players in Global Nosocomial Infection Treatment
Fig. 7 Global Ventilator Associated Pneumonia Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Urinary Tract Infection Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Blood Stream Infection Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Surgical Site Infection Market, 2015 - 2025 (US$ Mn)
Fig. 11 Global Gastrointestinal Infection Market, 2015 - 2025 (US$ Mn)
Fig. 12 Global MRSA Market, 2015 - 2025 (US$ Mn)
Fig. 13 Global Others (ENT Infections, Skin Infection, and Bone Infection) Market, 2015 - 2025 (US$ Mn)
Fig. 14 Global Antibacterial Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 15 Global Antiviral Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 16 Global Antifungal Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 17 Global Other Treatment Market, 2015 - 2025 (US$ Mn)erformance; Product Portfolio; News Coverage)
Table 19 Nordion: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 20 Pfizer: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 21 Roche: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 22 Sakura Seiki: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 23 BioMérieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 24 Steris: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 25 Johnson & Johnson: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 26 Sterigenics International, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 27 Halyard Health, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 28 Advanced Sterilization Products: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 29 Matachana Group: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott
  • Bayer
  • Becton, Dickinson and Company
  • Belimed
  • BioMerieux
  • Cantel
  • Cepheid
  • Getinge Group
  • Kimberly-Clark Corp.
  • Merck & Co
  • Nordion
  • Pfizer
  • Roche
  • Sakura Seiki
  • BioMérieux
  • Steris
  • Johnson & Johnson
  • Sterigeni
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll